ライフサイエンスコーパス: human immunodeficiency virus

1 ptive TB were enrolled (47% female; 32% with human immunodeficiency virus).

2 sepsis in immunocompromised patients without human immunodeficiency virus.

3 e largest study of cardiovascular disease in human immunodeficiency virus.

4 tabine (FTC) 200 mg among adults living with human immunodeficiency virus.

5 men, 2 key populations also at high risk for human immunodeficiency virus.

6 SEVI), that enhance the viral infectivity of human immunodeficiency virus.

7 antiretroviral therapy (ART) for adults with human immunodeficiency virus.

8 A large number of human immunodeficiency virus 1 (HIV-1) integrase (IN) al

9 Human immunodeficiency virus 1 (HIV-1) is a life-threate

10 Human immunodeficiency virus 1 (HIV-1) is a retrovirus w

11 at adds ac4C to RNAs, have been subverted by human immunodeficiency virus 1 (HIV-1) to increase viral

12 Human immunodeficiency virus 1 (HIV-1), the retroviral a

13 ark of CD4(+) T cells latently infected with human immunodeficiency virus 1 (HIV-1).

14 The majority of cells with latent human immunodeficiency virus 1 infection are located in

15 vere acute respiratory syndrome coronavirus, human immunodeficiency virus 1, hepatitis C virus, and J

16 TC) appear to retain modest activity against human immunodeficiency virus-1 with these mutations poss

17 Human immunodeficiency virus-2 infection represents a un

18 l load monitoring on 2489 people living with human immunodeficiency virus (age >=15 years).

19 As we have learned through years of treating human immunodeficiency virus and hepatitis C virus infec

20 itness landscape for the surface proteins of human immunodeficiency virus and hepatitis C virus.

21 could hinder efforts to end the intertwined human immunodeficiency virus and opioid overdose epidemi

22 ective cohort study, one-half of adults with human immunodeficiency virus and pulmonary tuberculosis

23 ease, sex with men (for men), infection with human immunodeficiency virus, and injection drug use.

24 rasites, syphilis, gonorrhea, chlamydia, and human immunodeficiency virus, as well as elevated blood

25 e receptor 5 (CCR5) is a key drug target for human immunodeficiency virus, cancer, and inflammation.

26 ted outcomes is not really known outside the human immunodeficiency virus co-infection setting.

27 Using partially validated data from a human immunodeficiency virus cohort, we illustrate the c

28 Rifampicin concentrations were lower with human immunodeficiency virus coinfection (median, 1.6 vs

29 Serological assays were performed on 85 human immunodeficiency virus-controller samples .

30 those with an immunocompromising condition (human immunodeficiency virus, diabetes, or malnutrition)

31 An established anti-human immunodeficiency virus drug target, CCR5 is attrac

32 like those of humans with cytomegalovirus, human immunodeficiency virus (even when under antiretrov

33 20 highly treatment-experienced persons with human immunodeficiency virus, extensive antiretroviral d

34 ease are main causes of death in people with human immunodeficiency virus (HIV) (PWH).

35 citabine is an effective means of decreasing human immunodeficiency virus (HIV) acquisition among wom

36 to prioritize individuals at higher risk of human immunodeficiency virus (HIV) acquisition for preve

37 is have been implicated in increased risk of human immunodeficiency virus (HIV) acquisition, but whet

38 in-containing contraceptives and the risk of human immunodeficiency virus (HIV) acquisition.

39 can significantly increase the incidence of human immunodeficiency virus (HIV) acquisition.

40 An outbreak of human immunodeficiency virus (HIV) among people who inje

41 infiltrate the central nervous system during human immunodeficiency virus (HIV) and cryptococcal meni

42 A) therapy has transformed the management of human immunodeficiency virus (HIV) and hepatitis C (HCV)

43 are each associated with the pathogenesis of human immunodeficiency virus (HIV) and hepatitis C virus

44 We assessed prevalence of testing for human immunodeficiency virus (HIV) and hepatitis C virus

45 bis use is frequent among people living with human immunodeficiency virus (HIV) and is associated wit

46 iate inflammation in adults living with both human immunodeficiency virus (HIV) and tuberculosis (TB)

47 sly described, including among patients with human immunodeficiency virus (HIV) and young women.

48 Multiple factors influence the human immunodeficiency virus (HIV) antibody response pro

49 Young adolescents with perinatally acquired human immunodeficiency virus (HIV) are at risk for poor

50 nfected with hepatitis B virus (HBV) and the human immunodeficiency virus (HIV) are at risk of develo

51 Increasingly, people living with human immunodeficiency virus (HIV) benefit from lower dr

52 advanced fibrosis in hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infected patients

53 Mycobacterium tuberculosis (Mtb) and human immunodeficiency virus (HIV) coinfection increases

54 We further tested the effect of human immunodeficiency virus (HIV) coinfection on diagno

55 spective study evaluated the reactivity of 3 human immunodeficiency virus (HIV) confirmatory assays (

56 reduced T-cell activation and exhaustion in human immunodeficiency virus (HIV) controllers start ant

57 A critical barrier to the development of a human immunodeficiency virus (HIV) cure is the lack of a

58 pensing registry of Madrid and the Liverpool human immunodeficiency virus (HIV) DDI database (January

59 Annual human immunodeficiency virus (HIV) diagnoses in the Unit

60 US guidelines recommend genotype testing at human immunodeficiency virus (HIV) diagnosis ("baseline

61 of multimorbidity (MM) according to year of human immunodeficiency virus (HIV) diagnosis in elderly

62 Advanced human immunodeficiency virus (HIV) disease (CD4 count <

63 Human immunodeficiency virus (HIV) drug resistance profi

64 The human immunodeficiency virus (HIV) epidemic among adoles

65 The human immunodeficiency virus (HIV) epidemic in India is

66 Cognitive dysfunction in human immunodeficiency virus (HIV) has decreased, but mi

67 The ongoing spread of human immunodeficiency virus (HIV) has driven novel inte

68 Human immunodeficiency virus (HIV) imparts increased hea

69 rventions may be an effective way to prevent human immunodeficiency virus (HIV) in adolescent girls a

70 (TB) and mortality among persons living with human immunodeficiency virus (HIV) in Latin America.

71 e health and renal impairment in people with human immunodeficiency virus (HIV) in resource-limited s

72 al (ARV) drugs are highly active against the human immunodeficiency virus (HIV) in the body compartme

73 markers of immune activation in persons with human immunodeficiency virus (HIV) in whom a sustained v

74 , of those, 90% virologically controlled) on human immunodeficiency virus (HIV) incidence, we conduct

75 Public health action combating human immunodeficiency virus (HIV) includes facilitating

76 ading cause of morbidity and mortality among Human Immunodeficiency virus (HIV) infected patients; ho

77 ortality and morbidity in people living with human immunodeficiency virus (HIV) infection (PLWH).

78 People with human immunodeficiency virus (HIV) infection (PWH) have

79 Human immunodeficiency virus (HIV) infection and antiret

80 tion contributes to immune activation during human immunodeficiency virus (HIV) infection and is usua

81 scents in sub-Saharan Africa are at risk for human immunodeficiency virus (HIV) infection and uninten

82 Children and adolescents with perinatal human immunodeficiency virus (HIV) infection and with lo

83 Human immunodeficiency virus (HIV) infection causes impa

84 Whether human immunodeficiency virus (HIV) infection impacts gut

85 etween the incidence of rectal gonorrhea and human immunodeficiency virus (HIV) infection in men who

86 ted that among people living with late-stage human immunodeficiency virus (HIV) infection initiating

87 Cotrimoxazole preventive therapy (CPT) in human immunodeficiency virus (HIV) infection is a World

88 Previous studies suggest that untreated human immunodeficiency virus (HIV) infection is associat

89 Human immunodeficiency virus (HIV) infection is characte

90 It is unclear whether human immunodeficiency virus (HIV) infection results in

91 Identification of nonviral markers of human immunodeficiency virus (HIV) infection that increa

92 on such as, diabetes, organ transplantation, Human immunodeficiency virus (HIV) infection, and elevat

93 ys in simian immunodeficiency virus (SIV) or human immunodeficiency virus (HIV) infection, and some r

94 eatening global infectious diseases, such as human immunodeficiency virus (HIV) infection, malaria an

95 ophan metabolism alterations are features of human immunodeficiency virus (HIV) infection, their inte

96 sub-Saharan Africa, often in the context of human immunodeficiency virus (HIV) infection.

97 els were built for patients with and without human immunodeficiency virus (HIV) infection.

98 ure prophylaxis (PrEP) for the prevention of human immunodeficiency virus (HIV) infection.

99 , Philadelphia identified an outbreak of new human immunodeficiency virus (HIV) infections among pers

100 disease management during the past decades, human immunodeficiency virus (HIV) infections are still

101 as not matched the pace of new treatments of human immunodeficiency virus (HIV) infections; neverthel

102 The concurrent treatment of tuberculosis and human immunodeficiency virus (HIV) is challenging, owing

103 The RNA genome of the human immunodeficiency virus (HIV) is reverse-transcribe

104 However, the impact on transmission of human immunodeficiency virus (HIV) is uncertain.

105 iretroviral therapy (ART) is recommended for human immunodeficiency virus (HIV) management.

106 Human immunodeficiency virus (HIV) may affect the risk o

107 titis C virus (HCV) among people living with human immunodeficiency virus (HIV) may be feasible in Au

108 Surveillance of human immunodeficiency virus (HIV) molecular diversity a

109 Mother-to-child transmission of human immunodeficiency virus (HIV) occurs in the setting

110 increasing injection drug use (IDU)-related human immunodeficiency virus (HIV) outbreaks, particular

111 tation, particularly in the absence of known human immunodeficiency virus (HIV) outbreaks.

112 analyzed 2007-2017 medical records data from Human Immunodeficiency Virus (HIV) Outpatient Study (HOP

113 Identifying where human immunodeficiency virus (HIV) persists in people li

114 Human immunodeficiency virus (HIV) persists indefinitely

115 coli dnaX mRNA and the gag-pol transcript of Human Immunodeficiency Virus (HIV) perturb translation e

116 antiretroviral therapy (ART), CD4+ count and human immunodeficiency virus (HIV) plasma viral load (PV

117 Human immunodeficiency virus (HIV) pre-exposure prophyla

118 Human immunodeficiency virus (HIV) preexposure prophylax

119 luated the feasibility of daily and nondaily human immunodeficiency virus (HIV) preexposure prophylax

120 r European counterparts, in addition to high human immunodeficiency virus (HIV) prevalence and risk o

121 lised epidemics of sub-Saharan Africa (SSA), human immunodeficiency virus (HIV) prevalence shows patt

122 rizes the results from systematic reviews of human immunodeficiency virus (HIV) prevention interventi

123 Human immunodeficiency virus (HIV) prevention interventi

124 The primary human immunodeficiency virus (HIV) reservoir is composed

125 hamphetamine (meth) injection and associated human immunodeficiency virus (HIV) risks among men who h

126 Despite low plasma human immunodeficiency virus (HIV) RNA, HIV controllers

127 years old, in Montreal, we compared observed human immunodeficiency virus (HIV) seroconcordance in pr

128 We estimated the time from human immunodeficiency virus (HIV) seroconversion to ant

129 age (<1 year, 1-4 years, adults), site, and human immunodeficiency virus (HIV) status (adults only)

130 uninfected controls and investigated whether human immunodeficiency virus (HIV) status is independent

131 We aimed to determine whether human immunodeficiency virus (HIV) status was independen

132 Among the patients in whom human immunodeficiency virus (HIV) status was known, 38%

133 fy current and future NCD burden in Kenya by human immunodeficiency virus (HIV) status.

134 traffic to the VS.IMPORTANCE The lentivirus human immunodeficiency virus (HIV) targets and destroys

135 d research exists on factors associated with human immunodeficiency virus (HIV) testing among people

136 Human immunodeficiency virus (HIV) testing and early dia

137 (ART) have made it possible for persons with human immunodeficiency virus (HIV) to live a near expect

138 Although mother-to-child human immunodeficiency virus (HIV) transmission has dram

139 With the widespread use of early human immunodeficiency virus (HIV) treatment, which virt

140 dampen chronic inflammation associated with human immunodeficiency virus (HIV) type 1.

141 peat viral load testing within 6 months when human immunodeficiency virus (HIV) viral loads exceed 1,

142 can drive inflammation in people living with human immunodeficiency virus (HIV) who have pulmonary tu

143 ascular Events in HIV) enrolled persons with human immunodeficiency virus (HIV) who were aged 40-75 y

144 oma cases, occurring in patients living with human immunodeficiency virus (HIV) who were on antiretro

145 ability for the syndemic of opioid overdose, human immunodeficiency virus (HIV), and hepatitis C viru

146 w education, violence, alcohol and drug use, human immunodeficiency virus (HIV), and stigma and discr

147 nt initiation rates among people living with human immunodeficiency virus (HIV), and then examined wh

148 ere tested for antiviral effects against the human immunodeficiency virus (HIV), followed by a compre

149 hout fully protective vaccines, particularly human immunodeficiency virus (HIV), malaria and tubercul

150 In human immunodeficiency virus (HIV), the relative contrib

151 IgG from patients chronically infected with human immunodeficiency virus (HIV), who typically exhibi

152 ntibody responses, have been shown to be key human immunodeficiency virus (HIV)-1 reservoirs.

153 Human immunodeficiency virus (HIV)-exposed, uninfected (

154 ic cotrimoxazole treatment is recommended in human immunodeficiency virus (HIV)-exposed, uninfected (

155 Among 284 human immunodeficiency virus (HIV)-hepatitis B virus (HB

156 rapy (HAART), lung disease remains common in human immunodeficiency virus (HIV)-infected (HIV+) adole

157 troviral therapy (cART)-treated, perinatally human immunodeficiency virus (HIV)-infected adolescents

158 The high incidence of KS in human immunodeficiency virus (HIV)-infected AIDS patient

159 Studies in human immunodeficiency virus (HIV)-infected individuals

160 tis C virus (HCV) prevalence/incidence among human immunodeficiency virus (HIV)-infected men who have

161 In 65 MSM, including 57 human immunodeficiency virus (HIV)-infected men with KS,

162 on the etiology of respiratory infections in human immunodeficiency virus (HIV)-infected patients in

163 Compared to human immunodeficiency virus (HIV)-negative cases, HIV t

164 Data from 1802 human immunodeficiency virus (HIV)-negative children age

165 ptomic data with new data from a prospective human immunodeficiency virus (HIV)-negative UK cohort of

166 In human immunodeficiency virus (HIV)-positive adults, low

167 er telmisartan reduces insulin resistance in human immunodeficiency virus (HIV)-positive individuals

168 We aimed to identify a human immunodeficiency virus (HIV)-related microbiota si

169 epatitis C virus (HCV) is a leading cause of human immunodeficiency virus (HIV)-related morbidity and

170 idence rates of liver injury among cotreated human immunodeficiency virus (HIV)-TB coinfected patient

171 -severe hepatic steatosis (M-HS) in PWH with human immunodeficiency virus (HIV)-uninfected controls a

172 including 30 elite controllers (ECs), and 30 human immunodeficiency virus (HIV)-uninfected controls w

173 One hundred forty-five human immunodeficiency virus (HIV)-uninfected pregnant w

174 stimated 200,000 people who have undiagnosed human immunodeficiency virus (HIV).

175 is increasingly recognized in people without human immunodeficiency virus (HIV).

176 9% were male and 70.4% were co-infected with human immunodeficiency virus (HIV).

177 influencing mother-to-child transmission of human immunodeficiency virus (HIV).

178 TIs) disproportionately impact patients with human immunodeficiency virus (HIV).

179 adly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV).

180 aging but generally younger population with human immunodeficiency virus (HIV).

181 ut its predictive power may be confounded by human immunodeficiency virus (HIV).

182 with future myocardial infarctions in hsCRP human immunodeficiency virus (HIV).

183 have sex with men (MSM) who were living with human immunodeficiency virus (HIV).

184 igh-profile data supporting its success with human immunodeficiency virus (HIV).

185 in treatment-experienced adults living with human immunodeficiency virus (HIV).

186 inst tuberculosis (TB) in people living with human immunodeficiency virus (HIV).

187 1)) in detecting p24 antigen as a marker for human immunodeficiency virus (HIV).

188 clinical outcomes among patients living with human immunodeficiency virus (HIV).

189 ildren in low-income communities affected by human immunodeficiency virus (HIV).

190 ant causes of death in persons with advanced human immunodeficiency virus (HIV)/acquired immunodefici

191 most common malignancy in people living with human immunodeficiency virus (HIV)/AIDS.

192 s impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected person

193 Chronic inflammation in human immunodeficiency virus (HIV)/hepatitis C virus (HC

194 disease (NAFLD) are common in patients with human immunodeficiency virus (HIV+ patients), but longit

195 People living with human immunodeficiency virus (HIV+) have greater risk fo

196 Human immunodeficiency virus (HIV-1) and herpes simplex

197 successful in controlling the replication of Human Immunodeficiency Virus (HIV-1) in many patients, c

198 impair weight gain among people living with human immunodeficiency virus (HIV; PLWH) starting efavir

199 genetic variability among people living with human immunodeficiency virus (HIV; PLWH), but remains un

200 al suppression (VS) among people living with human immunodeficiency virus (HIV; PLWH).

201 the characteristics of 31 people living with human immunodeficiency virus hospitalized for severe acu

202 in pregnant and postpartum women living with human immunodeficiency virus; however the relative contr

203 We estimated human immunodeficiency virus incidence and incidence rat

204 Human immunodeficiency virus-infected children had signi

205 d substantially reduce mortality rates among human immunodeficiency virus-infected persons in Africa.

206 Human immunodeficiency virus infection was also associat

207 isease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the mo

208 s (NRTIs) were the first drugs used to treat human immunodeficiency virus infection, and their use ca

209 Chronic inflammatory diseases including human immunodeficiency virus infection, psoriasis, rheum

210 In persons living with human immunodeficiency virus infection, such neuroprotec

211 NCE Brain injury induced by acute simian (or human) immunodeficiency virus infection may persist or s

212 several human-pathogenic viruses, including human immunodeficiency virus, influenza A virus, and yel

213 unrelated viruses including cytomegalovirus, human immunodeficiency virus, influenza virus, and dengu

214 The human immunodeficiency virus interacts with the cluster

215 hose with diabetes at baseline, those with a human immunodeficiency virus or hepatitis B virus coinfe

216 Among persons living with human immunodeficiency virus (PHIV), incident heart fail

217 impairment (NCI) in aging people living with human immunodeficiency virus (PLHIV) and people not livi

218 People living with human immunodeficiency virus (PLHIV) are at increased ri

219 matory syndrome (IRIS) in people living with human immunodeficiency virus (PLHIV) is rarely reported.

220 lled, with enrichment for people living with human immunodeficiency virus (PLHIV), within 72 hours of

221 disease (CVD) risk among persons living with human immunodeficiency virus (PLHIV).

222 Although people living with human immunodeficiency virus (PLWH) are at increased ris

223 People living with human immunodeficiency virus (PLWH) are commonly exclude

224 virologically suppressed persons living with human immunodeficiency virus (PLWH) switched from older

225 Patients living with human immunodeficiency virus (PLWH) with low CD4 counts

226 AH) is overrepresented in People Living with Human Immunodeficiency Virus (PLWH).

227 cognitive impairment in persons living with human immunodeficiency virus (PLWH).

228 infection is common among people living with human immunodeficiency virus (PLWH).

229 ease has been reported in people living with human immunodeficiency virus (PLWH).

230 Kaposi sarcoma is the most common cancer in human immunodeficiency virus-positive individuals and is

231 elaying second-line treatment initiation for human immunodeficiency virus-positive patients and morta

232 eceived treatment, of whom 77% (n = 23) were human immunodeficiency virus-positive, 47% (n = 14) had

233 ofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis.

234 Human immunodeficiency virus pre-exposure prophylaxis (P

235 In an observational study of persons with human immunodeficiency virus (PWH) and uninfected contro

236 prescribing trends among people living with human immunodeficiency virus (PWH) are not well describe

237 People with human immunodeficiency virus (PWH) demonstrate increased

238 People with human immunodeficiency virus (PWH) face increased risks

239 People living with human immunodeficiency virus (PWH) on antiretroviral the

240 Persons with human immunodeficiency virus (PWH) with persistently low

241 the first cause of morbidity in people with human immunodeficiency virus (PWH).

242 Interestingly, primer extension assays using human immunodeficiency virus reverse transcriptase (HIV-

243 ositive urine drug screens (P = .003), lower human immunodeficiency virus risk-taking behavior scores

244 Human immunodeficiency virus sequence data increased the

245 ues (RMs) (n = 13) were infected with simian/human immunodeficiency virus SHIV.C.CH505.375H.dCT, and

246 against repeated penile exposures to simian-human immunodeficiency virus (SHIV(SF162P3)).

247 rhesus macaques orally infected with simian/human immunodeficiency virus (SHIV) (SHIV.C.CH505) to id

248 Simian-human immunodeficiency virus (SHIV) infection of rhesus

249 We developed the following three new simian-human immunodeficiency virus (SHIV) stocks: SHIV-SF162p3

250 ed mice and one pivotal experiment in simian-human immunodeficiency virus (SHIV)-infected rhesus maca

251 A robust simian-human immunodeficiency virus (SHIV)-macaque model of lat

252 mian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV).

253 e model of intrarectal challenge with simian/human immunodeficiency virus (SHIV).

254 of HIV-1 latency and cure.IMPORTANCE Simian-human immunodeficiency viruses (SHIVs) have been success

255 tched for gestational age, maternal age, and human immunodeficiency virus status at time of enrollmen

256 Human immunodeficiency virus status was independently as

257 Human immunodeficiency virus status was independently as

258 from 250 to 8000 Hz included weekly AG dose, human immunodeficiency virus status with CD4 count, age,

259 tio 3.90; P < .001) after adjusting for age, human immunodeficiency virus status, and condom use.

260 Human immunodeficiency virus testing data revealed an in

261 tiretroviral therapy (ART) during home-based human immunodeficiency virus testing improved engagement

262 The human immunodeficiency virus type 1 (HIV-1) accessory pr

263 the first innate immune cells that encounter human immunodeficiency virus type 1 (HIV-1) after sexual

264 alum vaccine provided modest protection from human immunodeficiency virus type 1 (HIV-1) and simian i

265 uated the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1 (HIV-1) and vesicula

266 The human immunodeficiency virus type 1 (HIV-1) capsid (CA)

267 Mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) continues to

268 The "shock-and-kill" human immunodeficiency virus type 1 (HIV-1) cure strateg

269 Complex retroviruses like human immunodeficiency virus type 1 (HIV-1) encode the v

270 V stocks by optimization of a key residue in human immunodeficiency virus type 1 (HIV-1) Env (Env375)

271 We covalently attached human immunodeficiency virus type 1 (HIV-1) Env SOSIP tr

272 The human immunodeficiency virus type 1 (HIV-1) envelope gly

273 Millions are exposed to the human immunodeficiency virus type 1 (HIV-1) every year,

274 Human immunodeficiency virus type 1 (HIV-1) exploits a n

275 the release of ASLV in chicken cells and of human immunodeficiency virus type 1 (HIV-1) in human cel

276 tive impairment (SRNI) in people living with human immunodeficiency virus type 1 (HIV-1) infection is

277 Human immunodeficiency virus type 1 (HIV-1) infection pe

278 initiation for patients with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection, b

279 imens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection.

280 sm with contradictory data about its role in human immunodeficiency virus type 1 (HIV-1) infection.

281 Envelope (Env) glycoprotein of human immunodeficiency virus type 1 (HIV-1) is an import

282 ous z-scan studies failed to detect binding: human immunodeficiency virus type 1 (HIV-1) matrix (MA)

283 Human immunodeficiency virus type 1 (HIV-1) phylodynamic

284 Establishment of persistent human immunodeficiency virus type 1 (HIV-1) reservoirs o

285 l participants: baseline CD4 count, baseline human immunodeficiency virus type 1 (HIV-1) RNA, and CYP

286 A significant number of people living with human immunodeficiency virus type 1 (HIV-1) suffer from

287 onkeys is an important preclinical model for human immunodeficiency virus type 1 (HIV-1) vaccines, th

288 Mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) via breastfe

289 evelopment of therapeutic strategies against human immunodeficiency virus type 1 (HIV-1), but their a

290 adly neutralising antibodies (bNAbs) against human immunodeficiency virus type 1 (HIV-1), such as CAP

291 is indicated for treatment-naive adults with human immunodeficiency virus type 1 (HIV-1).

292 the surface of these cells upon infection by human immunodeficiency virus type 1 (HIV-1).

293 anemia virus (EIAV), and the Nef protein of human immunodeficiency virus type 1 (HIV-1).

294 known about impact of genetic divergence of human immunodeficiency virus type 1 group O (HIV-1/O) re

295 Here, we show that human immunodeficiency virus type-1 (HIV-1) with HBV-ass

296 sk of cardiovascular diseases in people with human immunodeficiency virus who were exposed to darunav

297 tly among women who had partners living with human immunodeficiency virus, who were not pregnant, and

298 Women living with human immunodeficiency virus (WLHIV) have disproportiona

299 ncentrations in hair among women living with human immunodeficiency virus (WLHIV) in the United State

300 ctors among a subset of cisgender women with human immunodeficiency virus (WWH) enrolled in the REPRI